Craig Hallum initiated coverage on shares of Cardiff Oncology (NASDAQ:CRDF – Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $8.00 price objective on the stock.
Cardiff Oncology Stock Up 9.5 %
Shares of NASDAQ CRDF opened at $2.31 on Friday. The stock has a market capitalization of $103.31 million, a P/E ratio of -2.57 and a beta of 1.95. The firm’s 50-day moving average price is $2.30 and its two-hundred day moving average price is $3.30. Cardiff Oncology has a 52-week low of $0.94 and a 52-week high of $6.42.
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.12 million. Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. During the same quarter in the prior year, the firm earned ($0.25) EPS. As a group, equities research analysts expect that Cardiff Oncology will post -1 earnings per share for the current year.
Institutional Trading of Cardiff Oncology
About Cardiff Oncology
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Featured Stories
- Five stocks we like better than Cardiff Oncology
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Block’s Key Components Make It a Solid Investment Choice
- How to Use the MarketBeat Stock Screener
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- What Are Dividends? Buy the Best Dividend Stocks
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.